Every two minutes, a man is diagnosed with prostate cancer in our country. This disease is currently the second-leading cancer-related killer of men in the United States.

Every two minutes, a man is diagnosed with prostate cancer in our country. This disease is currently the second-leading cancer-related killer of men in the United States.

An imaging test helps health care providers better understand what may be wrong with you so they can make treatment decisions or rule out certain health problems. There are many different types of ...

Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access information on a device and to provide personalised ads and content, ad and ...

A new review led by researchers at Moffitt Cancer Center assessed how three genomic tests — Decipher, Oncotype DX Genomic Prostate Score (GPS) and Prolaris — can help doctors make better decisions ...

Genomic tests give us a clearer picture of how aggressive prostate cancer might be. While these tests show promise, we need more well-designed studies to see exactly how they can improve treatment ...

authors call for well-designed trials on role of GC tests in newly diagnosed PCa. (HealthDay News) — For patients with localized prostate cancer (PCa), tissue-based genomic classifiers (GCs ...

YouTube said Wednesday that it is adding new experimental features for Premium users, including high-quality audio, a faster playback speed option on mobile, and the ability to “jump ahead” on ...

Get these health and wellness insights emailed to you three times a week. With our LiveWell app and website, you can manage health and wellness for yourself and for everyone who counts on you.

A systematic review found that genomic classifier tests can influence risk assessments and treatment decisions among patients with localized prostate cancer but studies evaluating these tests vary ...

Prostate cancer has proved an elusive target for cancer immunotherapies, and Merck & Co's checkpoint inhibitor Keytruda is the latest to fall short in the disease in a phase 3 trial. Merck has ...

On a foggy day at Ferrari’s Fiorano test track at its Maranello headquarters, Hamilton finally got to live his dream, sitting behind the wheel of the red car for the first time. To see him wear ...